What are the first‑line pharmacologic options and dosing schedules for smoking cessation, including varenicline, bupropion, and nicotine‑replacement therapy?

First-Line Pharmacologic Options for Smoking Cessation

The preferred first-line pharmacologic treatments for smoking cessation are combination nicotine replacement therapy (nicotine patch plus short-acting NRT) or varenicline monotherapy, both used for 12 weeks alongside behavioral counseling. 1

Preferred First-Line Regimens

The NCCN guidelines designate two equally preferred options—patients should select one of these approaches, not both simultaneously: 1

Option 1: Varenicline Monotherapy

Dosing schedule: 2, 1, 3

• Days 1–3: 0.5 mg once daily
• Days 4–7: 0.5 mg twice daily
• Weeks 2–12: 1 mg twice daily (if tolerated)
• Initiate 1–2 weeks before the target quit date 2, 3

Extended therapy: An additional 12 weeks (total 24 weeks) is recommended for successful quitters to increase long-term abstinence 2, 3

Mechanism: Varenicline is a partial agonist at α4β2 nicotinic acetylcholine receptors, providing sustained moderate dopamine release to reduce withdrawal while blocking nicotine's rewarding effects 2

Option 2: Combination Nicotine Replacement Therapy

Regimen: 2, 1

• Nicotine patch: 21 mg/day (or 14 mg/day for light smokers consuming <10 cigarettes/day)
• Plus short-acting NRT: Gum, lozenge, inhaler, or nasal spray for breakthrough cravings
• Duration: Minimum 12 weeks 2, 1

Rationale: Combining long-acting (patch) with short-acting NRT addresses both baseline nicotine levels and acute cravings, proving more effective than single-form NRT 2

Alternative First-Line Option: Bupropion

Dosing schedule: 2

• Days 1–3: 150 mg once daily
• Days 4 through week 12: 150 mg twice daily (maximum 300 mg/day)
• Initiate 1–2 weeks before quit date 2

Efficacy: Bupropion increases cessation rates compared to placebo (RR 1.69) but is less effective than varenicline (RR 0.73) and combination NRT 2, 4

Comparative Efficacy

Varenicline demonstrates superior efficacy to all other monotherapies: 2, 5, 6

• Varenicline vs. placebo: 2–3 fold increase in cessation 2
• Varenicline vs. bupropion: RR 1.37 favoring varenicline 4
• Varenicline vs. single-form NRT: Superior outcomes 5
• Combination NRT vs. bupropion: Combination NRT more effective 4

Behavioral Counseling Requirement

All pharmacotherapy must be combined with behavioral counseling—a minimum of 4 counseling sessions over 12 weeks is required. 2 The combination of counseling with medications is superior to either approach alone 2

Safety Considerations and Contraindications

Varenicline

Common adverse effects: 2, 3

• Nausea (up to 30% incidence, usually mild)
• Abnormal dreams and sleep disturbances
• Headache

Critical contraindication: Varenicline should not be used in patients with brain metastases due to seizure risk 2

Neuropsychiatric monitoring: The EAGLES trial (n=8,058) found no significant increase in neuropsychiatric adverse events with varenicline versus placebo in patients with or without psychiatric disorders 2. However, postmarketing reports include depression, suicidal ideation, and behavioral changes—monitor patients and instruct them to discontinue if these occur 3

Bupropion

Contraindications: 2

• Seizure disorders or conditions lowering seizure threshold (stroke, brain metastases)
• Concurrent MAO inhibitor use
• Concurrent tamoxifen use
• Closed-angle glaucoma

Nicotine Replacement Therapy

Safety in cardiovascular disease: NRT has been tested successfully without adverse effects in patients with coronary heart disease 2

Management of Treatment Failure

If initial therapy fails, switch to the alternative preferred option before considering combination therapy: 2, 1

After failed combination NRT: 2, 1

• Switch to varenicline monotherapy, or
• Continue/resume combination NRT with intensified behavioral therapy

After failed varenicline: 2, 1

• Switch to combination NRT + bupropion (Category 2B evidence), or
• Continue varenicline with dose adjustment or extended duration

Other optimization strategies: 2

• Increase medication doses (within approved limits)
• Extend treatment duration beyond 12 weeks
• Retreat with varenicline after addressing factors contributing to initial failure

Special Populations

Patients with psychiatric comorbidities: Varenicline or NRT are recommended first-line options 2. The EAGLES trial demonstrated safety in this population 2

Patients with COPD: Varenicline or NRT are preferred 7

Hospitalized patients: NRT is the treatment of choice 8

Severe renal impairment (CrCl <30 mL/min): 3

• Varenicline: Start 0.5 mg once daily, titrate to 0.5 mg twice daily
• End-stage renal disease on hemodialysis: Maximum 0.5 mg daily

Common Pitfalls to Avoid

• Do not combine varenicline with NRT as initial therapy—insufficient evidence supports this approach, and it increases adverse effects (nausea, headache, vomiting) without clear benefit 2
• Do not use varenicline in patients with brain metastases—seizure risk is elevated 2
• Do not prescribe pharmacotherapy without behavioral counseling—combination therapy is essential for optimal outcomes 2
• Do not discontinue therapy prematurely—minimum 12-week duration is required, with extended therapy improving long-term abstinence 2, 3